Study of Repeat Intranodal Injections of Ad-ISF35

Summary

This is a Phase II, open label, fixed dose, repeat injection, single institution study. Eligible subjects will receive up to six doses of Ad-ISF35 injected directly into a selected lymph node under ultrasound guidance. The primary goal is to determine and monitor clinical and biological responses in patients treated with repeat intranodal injections of Ad-ISF35.

Timeline

Start

2009-06

Primary completion

2009-07

Completion

2014-07

Outcome

Outcome not reported

Stopped: “drug supply was no longer available”

Drugs

Indications